tpp_sanfran

 

TPP China Forum

 

1-on-1 Partnering Event, San Francisco

Jan 14-16th, 2015

 

In association with OneMedForum and supported by Life Science Leader

HUGE SUCCESS!

We had over 250 partnered meetings take place across two action-packed days in San Francisco, between 25 Chinese companies and 70 US or European companies.

During many meetings, deal terms were discussed and follow-up actions were agreed upon. The TPP team is now carefully following all prospective deals to help ensure that the initial face-to-face meetings at the China Forum result in agreements.

We also received fantastic feedback surrounding the educational panel sessions:

  • Investing in America (Legend Capital, Sequoia Capital, OrbiMed, New Horizon)
  • How To Build A Successful Partnership (The Medicine Company, SciClone)
  • Optimal Deal Structures (WSGR, KPMG, Jun He)

WHAT YOU MISSED

DELEGATES FROM CHINA

Hony Capital, founded in 2003 and sponsored by Legend Holdings Corporation, is a leading private equity firm in China. As a China-focused investment firm with about US$7.0 billion assets under management, Hony employs “value creation by providing value added services” investment philosophy to increase the intrinsic value of its portfolio companies. The investors of Hony Capital include leading institutional investors across the world and in China.
Visit Website
Legend Capital is now managing six USD funds and three RMB funds with assets under management over RMB18.5 billion, and focuses on innovation and growth enterprises with operations in China or related to China. By October 2014, Legend Capital invested in over 200 companies, of which 29 have already been listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange, GEM and ChiNext of Shenzhen Stock Exchange; another 14 companies achieved exit through M&A. Legend Capital has an investment team with over 50 professionals, including 20 partners. Visit Website
Stone Capital is one of the largest fund management firms. Its clients include the local government, universities, and other foundations, and its asset under management is over 4 billion RMB.
More than 100 outstanding Chinese entrepreneurs and families are limited partners (LPs), such as Yongda, Dahua, Fosun(SH:600196), Shanshan(SH:600884), Pengxin, Zhida, Nine City, Hongdou(SH:600400), Bao Xi Niao(SZ:002154), Honghui Investment, Shenyin&Reihao, E-House(NYSE:EJ), Maipu, Yifang Property, Tuowei(SZ:002261), and Lonking(HK:3339). Many are ranked by Forbes as the most successful entrepreneurs in China, having made an enormous contribution to Chinese economic development. Its core team has a diversified background, coming from state-owned companies, commercial banks, foreign & local investment banks, and professional service institutions, such as Daiwa-SSC, Lehman Brothers, Morgan Stanley, Citigroup, Ernst Young, and Grandall Legal Group, and with a deep understanding of risks and opportunities in China.
Visit Website
Yangtze River Pharmaceutical Group is a privately held Chinese company with an annual revenue of $3.5 billion USD in 2012, making it a Top 3 pharmaceutical company in China. Its current portfolio and pipeline focus on anti-inflammatory, anticancer, cardiovascular, digestive, painkillers, and internal secretion drugs. It has well-known products such as Weisu granules, Gingko leaf tablets, and dizocine injection. They will be represented by Mr. Wang Haisheng, Vice General Manager.Visit Website
Founded in 2005, New Horizon is a leading China-focused private equity fund. It is managed by a group of seasoned investment professionals with local and overseas educational background as well as diversified and in-depth local knowledge and practical deal execution capabilities.
Visit Website
Adopting the innovative model of “training of entrepreneurs” + “angel investment” + “open platform,” this division actively promotes the transfer of science and technology research results into products and business, and the incubation of early technology startups. Legend Holdings wants to make substantive breakthroughs in commercializing technological findings, solving funding, talent, and resource problems faced by technology startups. As a result, Legend Star entered the world of venture capital investment and has since backed hundreds of startups, sharing the journey with startup entrepreneurs and acquiring a deeper understanding of the development of technology startups.
Visit Website
 Tasly was founded on May 1994. and has become a hi-tech group whose scope of business includes modern TCM, chemical medicine, biological medicine, healthcare products, functional food, covering the fields of research and development, planting, manufacturing, and distribution. Visit Website
 Wego Holding is a publicly traded Hong Kong company with market capitalization of $1.4 billion USD. Its current portfolio and pipeline focus on infusion sets, syringes, blood transfusion equipment, heart stents, cardiac consumables, IV catheters and special needles, blood purification equipment and consumables, orthopedic materials, operating room equipment and accessories, wound care products, minimally invasive instruments and equipment, ICU products and accessories, high-capacity injections and pharmaceuticals, renal products, biological diagnostic reagents, and PVC and non-PVC materials. Its products have been exported to the US and Europe. Wego Holding will be represented by Mr. Xing Jiangdong, Director of Strategic Investment.  Visit Website
 Salubris is a publicly traded Chinese company with a market capitalization of $168 million USD. Its current portfolio and pipeline focus on cardiovascular, anti-infection, anti-cancer, and diabetes pharmaceuticals. They also distribute invasive medical devices. They will be represented by Mr. Shu Xiao, Director of Business Development. Visit Website
Novotek Therapeutics is a privately held company that has revenue of $42 million USD in 2012. The company specializes in regulatory, marketing, and distribution of international products within China. Over the 8 past years, Novotek has successfully partnered with 22 different foreign companies across three continents. They will be represented by Dr. Lui Jubo, CEO. Visit Website
Kelun Pharmaceuticals is a publicly traded company with a market capitalization of $3.5 billion USD. They are the largest company specializing in IV solutions. Their current portfolio and pipeline focus on parenteral nutrition, digestive, cardiovascular, antipsychotics, antibiotics, and cancer. Kelun plans to set up a wholly-owned subsidiary in the US. Their delegation will include Mr. Ye Hong, Director, and Ms. Gu Guibao, Scientist. Visit Website
Nhwa is a publicly traded Chinese company with a market capitalization of $1.63 billion USD, making it the top Chinese company that specializes in CNS. Its current portfolio and pipeline focus on CNS and cardiovascular. Nhwa has licensed products from overseas companies. They will be represented by Ms. Ma Yanqin, Manager, and Mr. Sun Pengsheng, Chairman. Visit Website
Improve Medical is a publicly traded Chinese company with a market capitalization of $590 million USD. Its current portfolio and pipeline focus on medical consumables, IVD, and blood collection. It has set up a wholly-owned subsidiary in the US. They will be represented by Mr. Liu Ziye, President and CEO. Visit Website
Haisco is a publicly traded Chinese company with a market capitalization of $3.1 billion USD. Its lead products include: dolasetron mesylate-tumor adjuvant, prevention and treatment of nausea and vomiting, injection of trace elements-parenteral nutrition. Its current portfolio and pipeline focus on parenteral nutrition, first-aid drugs, antibiotics, anesthetic agents, nervous system, digestive system, and tumor adjuvant. They will be represented by Mr. Zheng Wei, Vice President and Mr. Liu Jianyu, Manager. Visit Website
Beijing Four Ring is a publicly traded Chinese company with a market capitalization of $942 million USD. Its current portfolio and pipeline focus on biological agents, chemical drugs, anticancer drugs, diagnostic reagents, and genetic engineering drugs. Its lead products are all biopharmaceutical engineering drugs. They will be represented by Mr. Cheng Dusheng, General Manager. Visit Website
 Shanghai Huaxin High Biotechnology is a privately held Chinese company that has an extensive distribution network that focuses on gynecology. Its main products are Recombinant Human Interferon α2b Vaginal Effervescent Capsules, Recombinant Human Interferon α2b Injection, and Recombinant Human Interleukin-2 for Injection. They will be represented by Mr. Wang Yang, Chairman, and Ms. Liu Hui, Deputy General Manager. Visit Website
Staidson is a publicly traded company with a market capitalization of $970 million USD. Staidson is a well-known biopharmaceutical company with an IND called Mouse Nerve Growth Factor for Injection, which could cure the impairment of the optic nerve. Its current portfolio and pipeline focus on immunological diseases and diabetes. They will be represented by Mr. Jiang Lixin, Director, and Mr. Zhou Guanghui, Director. Visit Website
Yongning Pharmaceuticals is a privately held pharmaceutical company that manufactures intermediates, APIs, and chemical drug agents. They will be represented by Mr. Ye Tianjian, General Manager, Mr. Li Jianwen, Executive Vice President, and Mr. Chen Xin, Director. Visit Website
Zhejiang East-Asia Pharmaceutical Co. is a privately held Chinese company that manufactures APIs. They aim to develop additional products in the areas of cardiovascular, anticancer, and antibiotics. They will be represented by Mr. Chi Cheng, Deputy GM, and Wu Siqing, Deputy GM. Visit Website
Datang is a privately held Chinese company specializing in traditional Chinese medicine and Mongolian medicine and seeking dermatology products. They will be represented by Ms. Sun Yali, Manager, and Ms. Liu Hongbin, Manager. Visit Website
Meilekang is distributor of healthcare products. They will be represented by Mr. Fang Yisheng, Chairman, and Mr. Jin Bo, General Manager. Visit Website
Sequoia Capital China Visit Website
Boehringer Ingelhelm China Visit Website

The Venue

Marriott Marquis
Union Square
San Francisco